• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Prenetics Global Limited

    3/27/23 10:59:56 AM ET
    $PRE
    Blank Checks
    Finance
    Get the next $PRE alert in real time by email
    SC 13D 1 d485570dsc13d.htm SC 13D SC 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No.     )*

     

     

    Prenetics Global Limited

    (Name of Issuer)

    Class A ordinary shares, US$0.0001 par value per share

    (Title of Class of Securities)

    G72245106

    (CUSIP Number)

    For Excelsiors Limited

    Tzang Chi Hung Lawrence

    Unit 701-706, K11 Atelier King’s Road

    728 King’s Road, Quarry Bay

    Hong Kong

    Tel: +852-2210-9588

    January 13, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


        SCHEDULE 13D    Page 2 of 8

    CUSIP No. G72245106

     

      (1)    

      Names of reporting persons

     

      For Excelsiors Limited

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      OO

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      (6)  

      Citizenship or place or organization

     

      British Virgin Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)   

      Sole voting power

     

      3,840,716

         (8)  

      Shared voting power

     

         (9)  

      Sole dispositive power

     

      3,840,716

       (10)  

      Shared dispositive power

     

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      3,840,716

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    (13)  

      Percent of class represented by amount in Row (11)

     

      2.42%(1)

    (14)  

      Type of reporting person (see instructions)

     

      CO

     

    (1)

    Calculated based on 158,820,280 ordinary shares of the Issuer (being the sum of 136,775,834 Class A ordinary shares and 22,044,446 Class B ordinary shares) to which this report is related, issued and outstanding as of January 12, 2023. The Class B ordinary shares are treated as converted into Class A ordinary shares only for the purpose of calculating the percentage of ownership of the Reporting Person.


    CUSIP No. G72245106

     

      (1)    

      Names of reporting persons

     

      Tzang Chi Hung Lawrence

      (2)  

      Check the appropriate box if a member of a group (see instructions)

      (a)  ☐        (b)  ☐

     

      (3)  

      SEC use only

     

      (4)  

      Source of funds (see instructions)

     

      OO

      (5)  

      Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

      (6)  

      Citizenship or place or organization

     

      Hong Kong SAR

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

     

         (7)   

      Sole voting power

     

      8,043,175(1)

         (8)  

      Shared voting power

     

         (9)  

      Sole dispositive power

     

      8,043,175(1)

       (10)  

      Shared dispositive power

     

    (11)    

      Aggregate amount beneficially owned by each reporting person

     

      8,043,175(1)

    (12)  

      Check if the aggregate amount in Row (11) excludes certain shares (see instructions)

     

    (13)  

      Percent of class represented by amount in Row (11)

     

      5.06%(2)

    (14)  

      Type of reporting person (see instructions)

     

      IN

     

    (1)

    Represents (i) 4,202,459 Class A ordinary shares directly held by Tzang Chi Hung Lawrence, and (ii) 3,840,716 Class A ordinary shares held by For Excelsiors Limited, a British Virgin Islands company that is wholly owned by Tzang Chi Hung Lawrence,

    (2)

    Calculated based on 158,820,280 ordinary shares of the Issuer (being the sum of 136,775,834 Class A ordinary shares and 22,044,446 Class B ordinary shares) to which this report is related, issued and outstanding as of January 12, 2023. The Class B ordinary shares are treated as converted into Class A ordinary shares only for the purpose of calculating the percentage of ownership of the Reporting Person.


      SCHEDULE 13D    Page 4 of 8

    Item 1. Security and Issuer.

    This Schedule 13D relates to the Class A ordinary shares, par value US$0.0001 per share (the “Class A Ordinary Shares”), of Prenetics Global Limited (the “Issuer”), an exempted company limited by shares incorporated under the laws of the Cayman Islands. The Class A Ordinary Shares are listed on the Nasdaq Stock Market LLC under the symbol “PRE.” The principal executive offices of the Issuer are located at Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong.

    Item 2. Identity and Background.

    (a): This Schedule 13D is being filed jointly by For Excelsiors Limited and Mr. Tzang Chi Hung Lawrence (“Lawrence”, together with For Excelsiors Limited, the “Reporting Persons,” and each, a “Reporting Person”) pursuant to Rule 13d-1(c) promulgated by the SEC under Section 13 of the Act. The agreement between the Reporting Persons relating to the joint filing of this Schedule 13D is attached hereto as Exhibit A.

    (b), (c) and (f): For Excelsiors Limited is a company incorporated in the British Virgin Island whose registered office address is Coastal Building, Wickham’ s Cay II, P. 0. Box 2221, Road Town, Tortola, VG 1110, British Virgin Islands. For Excelsiors Limited is wholly owned by Lawrence, the chief scientific officer of the Issuer. The principal business of For Excelsiors Limited is holding the shares of the Issuer.

    Lawrence is a citizen of Hong Kong SAR. Lawrence is the chief scientific officer of the Issuer. The business address of Lawrence is Unit 701-706, K11 Atelier King’s Road, 728 King’s Road, Quarry Bay, Hong Kong.

    (d) and (e): During the last five years, none of the Reporting Persons has been: (i) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    Item 3. Source and Amount of Funds or Other Consideration.

    Item 4 below summarizes certain provisions of the Business Combination Agreement (as defined below) that pertain to the securities acquired by the Reporting Persons. Prior to consummation of the Business Combination (as defined below), Lawrence beneficially owned 1,889,095 ordinary shares of Prenetics Group Limited, an exempted company limited by shares incorporated under the laws of the Cayman Islands (“Prenetics”) through For Excelsiors Limited. Upon consummation of the Business Combination (as defined below), For Excelsiors Limited received 3,840,716 Class A Ordinary shares in exchange for the shares held by For Excelsiors Limited in Prenetics.

    On October 21, 2022, Lawrence exercised 467,023 restricted share units in exchange for 949,503 Class A Ordinary Shares and on December 31, 2022, Lawrence exercised 1,600,000 restricted share units in exchange for 3,252,956 Class A Ordinary Shares pursuant to the Issuer’s 2022 Share Incentive Plan.


    Item 4. Purpose of Transaction.

    Business Combination

    On September 15, 2021, the Issuer entered into a Business Combination Agreement (as amended by an Amendment to Business Combination Agreement dated as of March 30, 2022 and as may be further amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”), by and among the Issuer, Artisan Acquisition Corp., an exempted company limited by shares incorporated under the laws of the Cayman Islands, AAC Merger Limited, an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of the Issuer (“Artisan Merger Sub”), PGL Merger Limited, an exempted company limited by shares incorporated under the laws of the Cayman Islands and a direct wholly-owned subsidiary of the Issuer (“Prenetics Merger Sub”) and Prenetics. Pursuant to the Business Combination Agreement, (i) Artisan merged with and into Artisan Merger Sub, with Artisan Merger Sub surviving and remaining as a wholly-owned subsidiary of the Issuer (the “Initial Merger”) and (ii) following the Initial Merger, Prenetics Merger Sub merged with and into Prenetics, with Prenetics being the surviving entity and becoming a wholly-owned subsidiary of the Issuer (the “Acquisition Merger”, and collectively with the Initial Merger and the other transactions contemplated by the Business Combination Agreement, the “Business Combination”). The Business Combination was consummated on May 18, 2022.

    As part of the Business Combination, each of the ordinary shares of Prenetics, par value $0.0001 per share, held by Lawrence was cancelled in exchange for 3,840,716 Class A Ordinary Shares.

    Registration Rights Agreement

    Concurrently with the execution of the Business Combination Agreement, the Issuer, Lawrence and certain other parties entered into a registration rights agreement (the “Registration Rights Agreement”), which became effective on May 18, 2022, pursuant to which, among other things, the Issuer agreed to undertake certain resale shelf registration obligations in accordance with the Securities Act of 1933, as amended and Sponsor and the equity holders of Prenetics have been granted customary demand and piggyback registration rights. Following the execution of the Business Combination Agreement and on November 8, 2021, all existing parties to the Registration Rights Agreement and several shareholders of Prenetics entered into a joinder agreement, pursuant to which such shareholders of Prenetics agreed to be bound by the terms and conditions of, and were granted the registration rights under, the Registration Rights Agreement.

    The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by the full text of the Registration Rights Agreement, which is attached as Exhibit B to this Schedule 13D and incorporated herein by reference.

    Share Incentive Plan

    On October 21, 2022, Lawrence exercised 467,023 restricted share units in exchange for 949,503 Class A Ordinary Shares pursuant to the Issuer’s 2022 Share Incentive Plan.

    On December 31, 2022, Lawrence exercised 1,600,000 restricted share units in exchange for 3,252,956 Class A Ordinary Shares pursuant to the Issuer’s 2022 Share Incentive Plan.


    General

    The Reporting Persons acquired the securities described in this Schedule 13D in connection with the closing of the Business Combination and exercise of restricted share units, and intend to review their investments in the Issuer on a continuing basis. Any actions the Reporting Person might undertake may be made at any time and from time to time without prior notice and will be dependent upon the Reporting Person’s review of numerous factors, including, but not limited to: an ongoing evaluation of the Issuer’s business, financial condition, operations and prospects; price levels of the Issuer’s securities; general market, industry and economic conditions; the relative attractiveness of alternative business and investment opportunities; and other future developments.

    The Reporting Persons may acquire additional securities of the Issuer, or retain or sell all or a portion of the securities then held, in the open market or in privately negotiated transactions. In addition, the Reporting Persons may engage in discussions with management, the Issuer’s board of directors, and other securityholders of the Issuer and other relevant parties or encourage, cause or seek to cause the Issuer or such persons to consider or explore extraordinary corporate transactions, such as: a merger, reorganization or take-private transaction that could result in the de-listing or de-registration of the Class A Ordinary Shares; sales or acquisitions of assets or businesses; changes to the capitalization or dividend policy of the Issuer; or other material changes to the Issuer’s business or corporate structure, including changes in management or the composition of the board of directors.

    Other than as described above, the Reporting Persons do not currently have any plans or proposals that relate to, or would result in, any of the matters listed in Items 4(a)–(j) of Schedule 13D, although, depending on the factors discussed herein, the Reporting Persons may change their purpose or formulate different plans or proposals with respect thereto at any time.

    Item 5. Interest in Securities of the Issuer.

    (a) and (b):

    The responses of each Reporting Person to Rows (7) through (13) of the cover pages of this Schedule 13D are hereby incorporated by reference in this Item 5.

    The percentage of the class of securities identified pursuant to Item 1 beneficially owned by the Reporting Person is based on a total of 158,820,280 issued and outstanding Ordinary Shares (consisting of 136,775,834 Class A Ordinary Shares and 22,044,446 Class B Ordinary Shares) of the Issuer as of January 12, 2023. Each Class B Ordinary Share is convertible at the option of the holder into one Class A Ordinary Share. Class A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. The rights of the holders of Class A Ordinary Shares and Class B Ordinary Shares are identical, except with respect to conversion rights (noted above) and voting rights. Each Class B Ordinary Share is entitled to twenty (20) votes, whereas each Class A Ordinary Share is entitled to one vote.

    The shares beneficially owned by For Excelsiors Limited represent approximately 2.42% of the total issued and outstanding ordinary shares of the Issuer and represent approximately 0.66% of the aggregate voting power of the Issuer’s total issued and outstanding ordinary shares.

    The shares beneficially owned by Lawrence represent approximately 5.06% of the total issued and outstanding ordinary shares of the Issuer and represent approximately 1.39% of the aggregate voting power of the Issuer’s total issued and outstanding ordinary shares.

    (c): Except as disclosed in this Schedule 13D, none of the Reporting Persons has effected any transaction in the Ordinary Shares during the past 60 days.

    (d): None.

    (e): Not applicable.


    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of the Issuer.

    Except as described above or elsewhere in this Schedule 13D or incorporated by reference in this Schedule 13D, the Reporting Persons do not have any contracts, arrangements, understandings or relationships (legal or otherwise) with any person with respect to any securities of the Issuer, including but not limited to any contracts, arrangements, understandings or relationships concerning the transfer or voting of such securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or losses, or the giving or withholding of proxies.

    Item 7. Materials to be Filed as Exhibits.

     

    Exhibit
    No.
      

    Description

    A    Joint Filing Agreement dated March 13, 2023 by and between the Reporting Persons.
    B    Registration Rights Agreement, dated as of September  15, 2021, by and among Prenetics Global Limited, Artisan Acquisition Corp., Artisan LLC, Danny Sheng Wu Yeung and other parties named therein (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form F-1 (File No. 333-265284) filed with the SEC on May 27, 2022).
    C    Shareholder Support Agreements and Deed, dated as of September  15, 2021, by and among Prenetics Global Limited, Prenetics Group Limited, Artisan Acquisition Corp., and certain management shareholders named therein (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form F-1 (File No. 333-265284) filed with the SEC on May 27, 2022).
    D    Amendment to Shareholder Support Agreement, dated as of March  30, 2022, by and among Prenetics Global Limited, Prenetics Group Limited, Artisan Acquisition Corp. and certain management shareholders named therein (incorporated by reference to Exhibit 10.23 to the Registration Statement on Form F-1 (File No. 333-265284) filed with the SEC on May 27, 2022).
    E    Prenetics Global Limited 2022 Share Incentive Plan (incorporated herein by reference to Exhibit 4.4 to the Form 20-F transition report filed with the SEC on May 27, 2022)


    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

                                                         Tzang Chi Hung Lawrence

     

    Date: March 21, 2023     Signature:  

    /s/ Tzang Chi Hung Lawrence

        Name:   Tzang Chi Hung Lawrence

                                                 For Excelsiors Limited

     

    Date: March 21, 2023     Signature:  

    /s/ Tzang Chi Hung Lawrence

        Name:   Tzang Chi Hung Lawrence
        Title:   Director
    Get the next $PRE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRE

    DatePrice TargetRatingAnalyst
    1/18/2023$7.00Overweight
    Cantor Fitzgerald
    7/12/2022Buy
    Citigroup
    More analyst ratings

    $PRE
    Financials

    Live finance-specific insights

    See more
    • Prenetics Announces Third Quarter 2024 Financial Results

      Revenue Grew 59.4% to $7.8 million from Prior Year and 30.9% Sequentially Officially Launched IM8Health.com, a new premium supplements brand Tencent Invests $30 million in Insighta's Early Cancer Detection Reiterates Revenue Target to Exceed $33 million for FY 2024 CHARLOTTE, N.C., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the third quarter ended September 30, 2024, along with recent business updates. Third Quarter 2024 Financial Highlights Revenue from continuing operations of $7.8 million, as compared to $4.9 million in the thi

      11/27/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Second Quarter 2024 Financial Results

      Cost Optimization Boosted Gross Margin by 21.7% YoY in H1 2024Enters U.S. Health Market in October with IM8, a New Health and Wellness BrandRe-affirms Revenue Target to Exceed US$33 million for FY 2024 CHARLOTTE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2024, along with recent business updates. Second Quarter 2024 Financial Highlights Revenue from continuing operations of US$5.9 million, as compared to US$6.5 million in the second quarter 2023 attributable to clinical segment revenues, which are anticipa

      10/7/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry

      Europa Is One of the Largest Sports Nutrition Distributors With a Network of 10,000+ Gyms Across the United States Supports Prenetics' New Health and Wellness Brand IM8 with David Beckham as its Co-Founding Partner Projected Revenue of $100 Million+ in Consumer Segment for FY2025 CHARLOTTE, N.C., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, is pleased to announce the acquisition of Europa Sports Partners ("Europa") and subsidiary, Hubmatrix, a global ecommerce and retail logistics provider. This strategic acquisition marks a significant milestone in Prenetics' expansion into the $1

      8/19/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Prenetics Group Ltd. with a new price target

      Cantor Fitzgerald initiated coverage of Prenetics Group Ltd. with a rating of Overweight and set a new price target of $7.00

      1/18/23 7:56:45 AM ET
      $PRE
      Blank Checks
      Finance
    • Citigroup initiated coverage on Prenetics Group Ltd.

      Citigroup initiated coverage of Prenetics Group Ltd. with a rating of Buy

      7/12/22 11:48:35 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Prenetics Global Limited

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/14/24 12:30:15 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      2/5/24 6:05:14 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by Prenetics Global Limited (Amendment)

      SC 13G/A - Prenetics Global Ltd (0001876431) (Subject)

      11/27/23 6:05:43 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    SEC Filings

    See more
    • SEC Form S-8 filed by Prenetics Global Limited

      S-8 - Prenetics Global Ltd (0001876431) (Filer)

      5/7/25 8:47:19 AM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 20-F filed by Prenetics Global Limited

      20-F - Prenetics Global Ltd (0001876431) (Filer)

      4/30/25 4:44:18 PM ET
      $PRE
      Blank Checks
      Finance
    • SEC Form 6-K filed by Prenetics Global Limited

      6-K - Prenetics Global Ltd (0001876431) (Filer)

      3/5/25 8:34:06 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IM8 Vibrante Miami: Fueling Wellness and Innovation with a Star-Studded Event

      David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8's Vision for Elite Wellness Accessible to All CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- On Monday, IM8, the premium supplement brand co-founded by David Beckham, hosted IM8 Vibrante - A Celebration of Science, Wellness & Flavor, a memorable evening at the iconic Faena Theater on Miami Beach. In attendance were nearly 150 wellness influencers, creators, science and medical advisors, and media members to celebrate the brand's ongoing commitment to transforming the status quo of wellness by blending innovation in science and medicine while prioritizing holistic he

      4/9/25 9:00:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

      Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University CHARLOTTE, N.C., March 18, 2025 (GLOBE NEWSWIRE) --  IM8, the premium supplements brand co-founded by David Beckham, today announced the addition of two distinguished new members, Dr. Jeremy London and Dr. Amy Shah, to its world-class Scientific Advisory Board (SAB). These additions underscore IM8's unwavering commitment to leading innovation in science, longevity and human performance. Newly joining IM8's SAB are: Dr. Amy Shah – An acclaimed integrative medicine physician and double board-certified expert in Internal Medicine, Dr. Shah focuses on g

      3/18/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics to Participate in the 37th Annual ROTH Conference

      CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA. Prenetics' Chief Executive Officer Danny Yeung and President of Americas David Vanderveen will be available to host one-on-one meetings with investors during the event. In addition, management will participate in a panel discussion on Longevity and Supplementation on Monday, March 17th at 12:00pm PT. Interested parties may access the panel through the webcast link here w

      3/11/25 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance

    $PRE
    Leadership Updates

    Live Leadership Updates

    See more
    • Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors

      LOS ANGELES, July 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading health sciences company, welcomes Kathryn M. Henry and David Vanderveen as independent directors to the Company's Board of Directors. "We are excited to welcome Kathryn and David to Prenetics' Board of Directors at this pivotal juncture," said Danny Yeung, CEO of Prenetics. "Their unparalleled expertise in consumer and health sectors, combined with their proven leadership in driving global expansion and operational excellence, will significantly enhance shareholder value as we expand into consumer health and wellness." "I am thrilled to join Prenetics at such a p

      7/1/24 8:30:00 AM ET
      $PRE
      Blank Checks
      Finance
    • Prenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space Station

      (From left: Dr. Ghada Alsaleh, Sonia Pawelczyk, Danny Yeung, Dr. James L. Green, Ahmed Alfandi, Dr. Tara Ruttley, Wasim Ahmed, Dr. Hilde Stenuit, Dr. Camille Alleyne at the MOU signing ceremony in Dubai, UAE Space Agency) Initial research project is with NDORMS, Botnar Research Institute, University of Oxford, focusing on accelerated aging in spaceDr. James L. Green, former Chief Scientist of NASA and Dr. Tara Ruttley, former Associate Chief Scientist of NASA to join Prenetics Scientific Advisory BoardInaugural research cube scheduled to be sent on-board SpaceX to the ISS in Q4 of 2024 DUBAI, United Arab Emirates, Feb. 09, 2024 (GLOBE NEWSWIRE) -- UAE Space Agency – Prenetics Global Li

      2/9/24 9:25:22 AM ET
      $PRE
      Blank Checks
      Finance